{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:27:48Z","timestamp":1787020068392,"version":"build-2736575974"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:00:00Z","timestamp":1726272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:00:00Z","timestamp":1726272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"DOI":"10.1186\/s12865-024-00651-x","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T22:01:57Z","timestamp":1726264917000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["\u03b2-glucan combined with Envafolimab and Endostar as immune rechallenge for metastatic non-small cell lung cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Qian","family":"Geng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanqun","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjian","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanbin","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,14]]},"reference":[{"key":"651_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin."},{"key":"651_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","volume":"22","author":"A Lahiri","year":"2023","unstructured":"Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22:40.","journal-title":"Mol Cancer"},{"key":"651_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD. Acquired Resistance to Immune Checkpoint Inhibitors. Cancer Cell. 2020;37:443\u201355.","journal-title":"Cancer Cell"},{"key":"651_CR4","doi-asserted-by":"publisher","first-page":"1309055","DOI":"10.3389\/fimmu.2023.1309055","volume":"14","author":"H Zhang","year":"2023","unstructured":"Zhang H, Hu Y, Wu T, Chen Y, Yang B, Xie T. Clinical characteristics and novel strategies of immune checkpoint inhibitor rechallenge therapy for non-small cell lung cancer: a comprehensive review. Front Immunol. 2023;14:1309055.","journal-title":"Front Immunol"},{"key":"651_CR5","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.3390\/cancers16061196","volume":"16","author":"ME Livanou","year":"2024","unstructured":"Livanou ME, Nikolaidou V, Skouras V, Fiste O, Kotteas E. Efficacy of NSCLC Rechallenge with Immune Checkpoint Inhibitors following Disease Progression or Relapse. Cancers. 2024;16:1196.","journal-title":"Cancers"},{"key":"651_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102545","volume":"116","author":"A Desai","year":"2023","unstructured":"Desai A, Peters S. Immunotherapy-based combinations in metastatic NSCLC. Cancer Treat Rev. 2023;116: 102545.","journal-title":"Cancer Treat Rev"},{"key":"651_CR7","doi-asserted-by":"publisher","first-page":"1901071","DOI":"10.1002\/mnfr.201901071","volume":"65","author":"CE De Marco","year":"2021","unstructured":"De Marco CE, Calder PC, Roche HM. \u03b2-1,3\/1,6-Glucans and Immunity: State of the Art and Future Directions. Mol Nutr Food Res. 2021;65:1901071.","journal-title":"Mol Nutr Food Res"},{"key":"651_CR8","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1016\/j.vaccine.2018.07.038","volume":"36","author":"Y Jin","year":"2018","unstructured":"Jin Y, Li P, Wang F. \u03b2-glucans as potential immunoadjuvants: A review on the adjuvanticity, structure-activity relationship and receptor recognition properties. Vaccine. 2018;36:5235\u201344.","journal-title":"Vaccine"},{"key":"651_CR9","doi-asserted-by":"publisher","first-page":"1017475","DOI":"10.3389\/fphar.2023.1017475","volume":"14","author":"Y Xie","year":"2023","unstructured":"Xie Y, Shao F, Duan X, Ding J, Ning Y, Sun X, et al. Whole \u03b2-glucan particle attenuates AOM\/DSS-induced colorectal tumorigenesis in mice via inhibition of intestinal inflammation. Front Pharmacol. 2023;14:1017475.","journal-title":"Front Pharmacol"},{"key":"651_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jnutbio.2018.06.010","volume":"61","author":"J Muthukumaran","year":"2018","unstructured":"Muthukumaran J, Jiali C, Stephen C, Baojun X. A critical review on the impacts of \u03b2-glucans on gut microbiota and human health. J Nutr Biochem. 2018;61:101\u201310.","journal-title":"J Nutr Biochem"},{"key":"651_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.887457","volume":"13","author":"M Wang","year":"2022","unstructured":"Wang M, Bai Y, Pei J, Li D, Pu X, Zhu W, et al. \u03b2-Glucan Combined With PD-1\/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer. Front Pharmacol. 2022;13: 887457.","journal-title":"Front Pharmacol"},{"key":"651_CR12","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/celldisc.2017.4","volume":"3","author":"F Zhang","year":"2017","unstructured":"Zhang F, Wei H, Wang X, Bai Y, Wang P, Wu J, et al. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discovery. 2017;3:17004.","journal-title":"Cell Discovery"},{"key":"651_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40265-022-01671-w","volume":"82","author":"MA Envafolimab","year":"2022","unstructured":"Envafolimab MA. First Approval. Drugs. 2022;82:235\u201340.","journal-title":"Drugs"},{"key":"651_CR14","doi-asserted-by":"publisher","first-page":"7431","DOI":"10.1126\/scitranslmed.aav7431","volume":"12","author":"M Mayoux","year":"2020","unstructured":"Mayoux M, Roller A, Pulko V, Sammicheli S, Chen S, Sum E, et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Science Translational Medicine. 2020;12:7431.","journal-title":"Science Translational Medicine"},{"key":"651_CR15","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1002\/onco.13817","volume":"26","author":"KP Papadopoulos","year":"2021","unstructured":"Papadopoulos KP, Harb W, Peer CJ, Hua Q, Xu S, Lu H, et al. First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors. Oncologist. 2021;26:1514\u201325.","journal-title":"Oncologist"},{"key":"651_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13045-021-01095-1","volume":"14","author":"J Li","year":"2021","unstructured":"Li J, Deng Y, Zhang W, Zhou AP, Guo W, Yang J, et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair\/microsatellite instability high solid tumors. J Hematol Oncol. 2021;14:95.","journal-title":"J Hematol Oncol"},{"key":"651_CR17","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1111\/1759-7714.13483","volume":"11","author":"K Shingo","year":"2020","unstructured":"Shingo K, Taiki H, Rui K, Yukio H. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review. Thoracic Cancer. 2020;11:1927\u201333.","journal-title":"Thoracic Cancer"},{"key":"651_CR18","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/1759-7714.14309","volume":"13","author":"T Yutaka","year":"2022","unstructured":"Yutaka T, Takuya T, Yoko I, Ikuyo S, Kouichi Y, Takashi S, et al. Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non-small cell lung cancer. Thoracic Cancer. 2022;13:624\u201330.","journal-title":"Thoracic Cancer"},{"key":"651_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.03.009","volume":"179","author":"R Martin","year":"2023","unstructured":"Martin R, Sanjay P, Christian G, Jesus C, Silvia N, Maya G, et al. Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives. Lung Cancer. 2023;179: 107173.","journal-title":"Lung Cancer"},{"key":"651_CR20","first-page":"030","volume":"108","author":"K Elizabeth","year":"2016","unstructured":"Elizabeth K, Melissa Y, Avinoam B, Christina L, Henriett B, Shan M, et al. Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma. J Natl Cancer Inst. 2016;108:030.","journal-title":"J Natl Cancer Inst"},{"key":"651_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","volume":"18","author":"M Yi","year":"2019","unstructured":"Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18:60.","journal-title":"Mol Cancer"},{"key":"651_CR22","doi-asserted-by":"publisher","first-page":"109746","DOI":"10.1016\/j.biopha.2019.109746","volume":"125","author":"J Wu","year":"2020","unstructured":"Wu J, Zhao XG, Sun QF, Jiang YF, Zhang WQ, Luo JW, et al. Synergic effect of PD-1 blockade and endostar on the PI3K\/AKT\/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model. Biomed Pharmacother. 2020;125:109746.","journal-title":"Biomed Pharmacother"},{"key":"651_CR23","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jtho.2023.09.1172","volume":"18 Suppl","author":"X Jiang","year":"2023","unstructured":"Jiang X. EP11.02\u201310 Efficacy and Safety of Combining Envafolimab with Endostar in Advanced NSCLC: A Multi-Center Prospective Study (Endouble). J Thorac Oncol. 2023;18 Suppl:618\u20139.","journal-title":"J Thorac Oncol"},{"issue":"Suppl 3","key":"651_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102649","volume":"9","author":"S Yuan","year":"2024","unstructured":"Yuan S, Miao C. 70P Phase II clinical study of envafolimab combined with recombinant human endostatin and chemotherapy as a first-line treatment for driver gene-negative advanced non-small cell lung cancer. ESMO Open. 2024;9(Suppl 3): 102649.","journal-title":"ESMO Open"},{"key":"651_CR25","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.7150\/ijbs.82776","volume":"19","author":"H Han","year":"2023","unstructured":"Han H, Ke W, Rong J, Zixun Z, Min Z, Yuanle D, et al. Current Status in Rechallenge of Immunotherapy. Int J Biol Sci. 2023;19:2428\u201342.","journal-title":"Int J Biol Sci"},{"key":"651_CR26","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00280-019-03926-y","volume":"84","author":"M Atsuto","year":"2019","unstructured":"Atsuto M, Kyoichi K, Ou Y, Ayako S, Yu M, Kosuke H, et al. Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer. Cancer Chemother Pharmacol. 2019;84:873\u201380.","journal-title":"Cancer Chemother Pharmacol"},{"key":"651_CR27","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","volume":"6","author":"S Fernando","year":"2018","unstructured":"Fernando S, Hira R, Andrew P, Andy N, Mario L, Maya G, et al. Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. Cancer Immunol Res. 2018;6:1093\u20139.","journal-title":"Cancer Immunol Res"},{"key":"651_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103434","volume":"165","author":"A Inno","year":"2021","unstructured":"Inno A, Roviello G, Ghidini A, Luciani A, Catalano M, Gori S, et al. Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;165: 103434.","journal-title":"Crit Rev Oncol Hematol"},{"key":"651_CR29","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3389\/fimmu.2018.00341","volume":"9","author":"M Zhang","year":"2018","unstructured":"Zhang M, Kim JA, Huang AY. Optimizing Tumor Microenvironment for Cancer Immunotherapy: \u03b2-Glucan-Based Nanoparticles. Front Immunol. 2018;9:341.","journal-title":"Front Immunol"},{"key":"651_CR30","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/eji.201242841","volume":"43","author":"J Tian","year":"2013","unstructured":"Tian J, Ma J, Ma K, Guo H, Baidoo SE, Zhang Y, et al. \u03b2-Glucan enhances antitumor immune responses by regulating differentiation and function of monocytic myeloid-derived suppressor cells. Eur J Immunol. 2013;43:1220\u201330.","journal-title":"Eur J Immunol"},{"key":"651_CR31","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1002\/ijc.30002","volume":"138","author":"Y Ning","year":"2016","unstructured":"Ning Y, Xu D, Zhang X, Bai Y, Ding J, Feng T, et al. \u03b2-glucan restores tumor-educated dendritic cell maturation to enhance antitumor immune responses. Int J Cancer. 2016;138:2713\u201323.","journal-title":"Int J Cancer"},{"key":"651_CR32","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1517\/14712598.5.5.691","volume":"5","author":"J Yan","year":"2005","unstructured":"Yan J, Allendorf DJ, Brandley B. Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer. Expert Opin Biol Ther. 2005;5:691\u2013702.","journal-title":"Expert Opin Biol Ther"},{"key":"651_CR33","doi-asserted-by":"publisher","first-page":"6825","DOI":"10.1182\/blood-2011-02-339812","volume":"117","author":"C Qi","year":"2011","unstructured":"Qi C, Cai Y, Gunn L, Ding C, Li B, Kloecker G, et al. Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived \u03b2-glucans. Blood. 2011;117:6825\u201336.","journal-title":"Blood"},{"key":"651_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/cei\/uxad080","volume":"214","author":"Z Zhu","year":"2023","unstructured":"Zhu Z, He L, Bai Y, Xia L, Sun X, Qi C. Yeast \u03b2-glucan modulates macrophages and improves antitumor NK-cell responses in cancer. Clin Exp Immunol. 2023;214:50\u201360.","journal-title":"Clin Exp Immunol"},{"key":"651_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00430-018-0556-z","volume":"208","author":"J Ding","year":"2019","unstructured":"Ding J, Ning Y, Bai Y, Xu X, Sun X, Qi C. \u03b2-Glucan induces autophagy in dendritic cells and influences T-cell differentiation. Med Microbiol Immunol. 2019;208:39\u201348.","journal-title":"Med Microbiol Immunol"},{"key":"651_CR36","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00262-022-03276-4","volume":"72","author":"X Hu","year":"2023","unstructured":"Hu X, Shui Y, Hirano H, Kusano K, Guo WZ, Fujino M, et al. PD-L1 antibody enhanced \u03b2-glucan antitumor effects via blockade of the immune checkpoints in a melanoma model. Cancer Immunology, Immunotherapy: CII. 2023;72:719\u201331.","journal-title":"Cancer Immunology, Immunotherapy: CII"},{"key":"651_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2023.121564","volume":"324","author":"Q Wang","year":"2024","unstructured":"Wang Q, Jiang H, Zhang H, Lu W, Wang X, Xu W, et al. \u03b2-Glucan-conjugated anti-PD-L1 antibody enhances antitumor efficacy in preclinical mouse models. Carbohyd Polym. 2024;324: 121564.","journal-title":"Carbohyd Polym"},{"key":"651_CR38","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","volume":"15","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15:1111\u201322.","journal-title":"Hum Vaccin Immunother"},{"key":"651_CR39","doi-asserted-by":"publisher","first-page":"7139","DOI":"10.3390\/ijms21197139","volume":"21","author":"E Shklovskaya","year":"2020","unstructured":"Shklovskaya E, Rizos H. Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy. Int J Mol Sci. 2020;21:7139.","journal-title":"Int J Mol Sci"},{"key":"651_CR40","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s43018-020-0075-x","volume":"1","author":"SA Oh","year":"2020","unstructured":"Oh SA, Wu DC, Cheung J, Navarro A, Xiong H, Cubas R, et al. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nature Cancer. 2020;1:681\u201391.","journal-title":"Nature Cancer"},{"key":"651_CR41","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.21873\/anticanres.13543","volume":"39","author":"K Fujita","year":"2019","unstructured":"Fujita K, Uchida N, Yamamoto Y, Kanai O, Okamura M, Nakatani K, et al. Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies. Anticancer Res. 2019;39:3917\u201321.","journal-title":"Anticancer Res"},{"key":"651_CR42","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/1759-7714.13824","volume":"12","author":"F Naoki","year":"2021","unstructured":"Naoki F, Makoto N, Kazushige W, Satoshi I, Takashi S, Ryota U, et al. Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody. Thoracic Cancer. 2021;12:613\u20138.","journal-title":"Thoracic Cancer"},{"key":"651_CR43","doi-asserted-by":"publisher","first-page":"7175","DOI":"10.1002\/cam4.7175","volume":"13","author":"Z Yaxiong","year":"2024","unstructured":"Yaxiong Z, Zihong C, Yu L, Liang H, Wei J, Qiming W, et al. Chidamide plus envafolimab as subsequent treatment in advanced non-small cell lung cancer patients resistant to anti-PD-1 therapy: A multicohort, open-label, phase II trial with biomarker analysis. Cancer Med. 2024;13:7175.","journal-title":"Cancer Med"},{"key":"651_CR44","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","volume":"397","author":"A Sezer","year":"2021","unstructured":"Sezer A, Kilickap S, G\u00fcm\u00fc\u015f M, Bondarenko I, \u00d6zg\u00fcro\u011flu M, Gogishvili M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet (London, England). 2021;397:592\u2013604.","journal-title":"Lancet (London, England)"},{"key":"651_CR45","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.2217\/fon-2018-0639","volume":"15","author":"J Li","year":"2019","unstructured":"Li J, Gu J. PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1\/PD-L1 inhibitors: a meta-analysis. Future Oncology (London, England). 2019;15:1667\u201378.","journal-title":"Future Oncology (London, England)"},{"key":"651_CR46","first-page":"102","volume":"9","author":"K Yuki","year":"2020","unstructured":"Yuki K, Takayuki S, Tadaaki Y, Takayuki T, Takahiro Y, Shinsuke S, et al. Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer. J Clin Med. 2020;9:102.","journal-title":"J Clin Med"},{"key":"651_CR47","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00280-018-3585-9","volume":"81","author":"F Kohei","year":"2018","unstructured":"Kohei F, Naohiro U, Osamu K, Misato O, Koichi N, Tadashi M. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases. Cancer Chemother Pharmacol. 2018;81:1105\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"651_CR48","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1016\/j.jtcvs.2017.11.110","volume":"155","author":"E Ella","year":"2018","unstructured":"Ella E, Harel Y, Abraham M, Wald H, Benny O, Karsch-Bluman A, et al. Matrix metalloproteinase 12 promotes tumor propagation in the lung. J Thorac Cardiovasc Surg. 2018;155:2164\u201375.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"651_CR49","doi-asserted-by":"publisher","DOI":"10.1172\/JCI153643","volume":"132","author":"H Zhang","year":"2022","unstructured":"Zhang H, Zhu X, Friesen TJ, Kwak JW, Pisarenko T, Mekvanich S, et al. Annexin A2\/TLR2\/MYD88 pathway induces arginase 1 expression in tumor-associated neutrophils. J Clin Investig. 2022;132: 153643.","journal-title":"J Clin Investig"},{"key":"651_CR50","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1111\/cas.14932","volume":"112","author":"J Zou","year":"2021","unstructured":"Zou J, Xia H, Zhang C, Xu H, Tang Q, Zhu G, et al. Casp8 acts through A20 to inhibit PD-L1 expression: The mechanism and its implication in immunotherapy. Cancer Sci. 2021;112:2664\u201378.","journal-title":"Cancer Sci"},{"key":"651_CR51","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.3390\/ijms20112810","volume":"20","author":"WX Huff","year":"2019","unstructured":"Huff WX, Kwon JH, Henriquez M, Fetcko K, Dey M. The Evolving Role of CD8 + CD28- Immunosenescent T Cells in Cancer Immunology. Int J Mol Sci. 2019;20:2810.","journal-title":"Int J Mol Sci"},{"key":"651_CR52","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s12967-019-2097-7","volume":"17","author":"C Liu","year":"2019","unstructured":"Liu C, Jing W, An N, Li A, Yan W, Zhu H, et al. Prognostic significance of peripheral CD8+CD28+ and CD8+CD28- T cells in advanced non-small cell lung cancer patients treated with chemo(radio)therapy. J Transl Med. 2019;17:344.","journal-title":"J Transl Med"},{"key":"651_CR53","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/cac2.12010","volume":"40","author":"W Zhang","year":"2020","unstructured":"Zhang W, Wang H, Sun M, Deng X, Wu X, Ma Y, et al. CXCL5\/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target. Cancer Communications (London, England). 2020;40:69\u201380.","journal-title":"Cancer Communications (London, England)"},{"key":"651_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007310","volume":"11","author":"AR Naqash","year":"2023","unstructured":"Naqash AR, McCallen JD, Mi E, Iivanainen S, Marie MA, Gramenitskaya D, Clark J, et al. Increased interleukin-6\/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer. J Immunother Cancer. 2023;11: 007310.","journal-title":"J Immunother Cancer"},{"key":"651_CR55","doi-asserted-by":"publisher","first-page":"977","DOI":"10.2147\/JIR.S401123","volume":"16","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Wang XL, Liu JJ, Qian ZY, Pan ZY, Song NP, et al. ICOS\/ICOSLG and PD-1 Co-Expression is Associated with the Progression of Colorectal Precancerous- Carcinoma Immune Microenvironment. J Inflamm Res. 2023;16:977\u201392.","journal-title":"J Inflamm Res"},{"key":"651_CR56","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00262-007-0344-x","volume":"57","author":"RB Baleeiro","year":"2008","unstructured":"Baleeiro RB, Bergami-Santos PC, Tomiyoshi MY, Gross JL, Haddad F, Pinto CA, et al. Expression of a dendritic cell maturation marker CD83 on tumor cells from lung cancer patients and several human tumor cell lines: is there a biological meaning behind it? Cancer Immunology, Immunotherapy: CII. 2008;57:265\u201370.","journal-title":"Cancer Immunology, Immunotherapy: CII"},{"key":"651_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110232","volume":"127","author":"P Luo","year":"2020","unstructured":"Luo P, Deng S, Ye H, Yu X, Deng Q, Zhang Y, et al. The IL-33\/ST2 pathway suppresses murine colon cancer growth and metastasis by upregulating CD40 L signaling. Biomed Pharmacother. 2020;127: 110232.","journal-title":"Biomed Pharmacother"},{"key":"651_CR58","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.20892\/j.issn.2095-3941.2022.0540","volume":"19","author":"T Boch","year":"2022","unstructured":"Boch T, K\u00f6hler J, Janning M, Loges S. Targeting the EGF receptor family in non-small cell lung cancer\u2014increased complexity and future perspectives. Cancer Biol Med. 2022;19:1543\u201364.","journal-title":"Cancer Biol Med"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-024-00651-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-024-00651-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-024-00651-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T23:41:54Z","timestamp":1726270914000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-024-00651-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,14]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["651"],"URL":"https:\/\/doi.org\/10.1186\/s12865-024-00651-x","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,14]]},"assertion":[{"value":"20 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Changzhou No.2 People\u2019s Hospital (Approval number: [2021YLJSD002]) and conducted in accordance with the principles of the Declaration of Helsinki. All registered patients have signed informed consent forms to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}